A Cohort Establishment Study of Total Management of Ovarian Cancer

Ovarian Cancer Clinical Trial

Official title:

A Cohort Establishment Study of Total Management of Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06018935
• Other study ID #: LCATM202304
• Status: Recruiting
• Start date: June 17, 2024
• Est. completion date: September 1, 2025

Study information

• Verified date: June 2024
• Source: Sichuan Cancer Hospital and Research Institute
• Contact: Dengfeng Wang, Learned scholar
• Phone: 15982222707
• Email: wonderful_96[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Description:

1. To investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer);

2. To study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures;

3. The prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed;

4. To study the efficacy and safety of PARPi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: September 1, 2025
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital;

2. Can cooperate with later follow-up.

Exclusion Criteria:

1. Patients with other malignant tumors or previous history of other malignant tumors;

2. Have cognitive impairment.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Genital Neoplasms, Female
• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
China	Sichuan Cancer Hospital	Chengdu

Sponsors (1)

Lead Sponsor	Collaborator
Sichuan Cancer Hospital and Research Institute

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progress Freesurvival (PFS)	The time from the start of treatment until the patient progresses further or dies.	Average six months after study completion.
Primary	Overall Survival (OS)	Measure the time from the start of treatment to the time of death.	Average six months after study completion.
Secondary	Occurrence of adverse reactions	All adverse events were recorded.	Average six months after study completion.